 |
Kettering General Hospital |
 |
NHS Foundation Trust |
|
Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
Useful Links |
Chemotherapy Services - KGH Intranet (KGH Only) |
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
08.01 |
Cytotoxic drugs (0,0)
|
|

Side-effects of cytotoxic drugs
(0,1)
|
|

Drugs for cytotoxic-induced side-effects
(3,5)
|
08.01.01 |
Alkylating drugs
(8,5)
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(9,4)
|
08.01.03 |
Antimetabolites
(12,5)
|
08.01.04 |
Vinca alkaloids and etoposide
(4,7)
|
08.01.05 |
Other antineoplastic drugs
(15,5)
|
|

Amsacrine
(1,0)
|
|

CDK inhibitors (0,0)
|
|

Arsenic trioxide
(1,0)
|
|

Bevacizumab
(1,0)
|
|

Bexarotene
(0,1)
|
|

Bortezomib
(1,0)
|
|

Brentuximab vedotin
(1,0)
|
|

Cetuximab
(1,1)
|
|

Crisantaspase
(0,1)
|
|

Dacarbazine and Temozolomide
(1,1)
|
|

Erlotinib (0,0)
|
|

Hydroxycarbamide
(1,1)
|
|

Imatinab (0,0)
|
|

Mitotane
(0,1)
|
|

Panitumumab
(1,0)
|
|

Pentostatin
(0,1)
|
|

Platinum compounds
(3,1)
|
|

Porfimer sodium and temoporfin
(0,2)
|
|

Procarbazine
(1,0)
|
|

Protein kinase inhibitors
(21,11)
|
|

Tezanes
(2,2)
|
|

Topoisimerase I inhibitors
(2,1)
|
|

Trabectedin
(0,1)
|
|

Trastuzumab
(2,0)
|
|

Tretinoin
(1,0)
|
|

Vismodegib
(0,1)
|
08.02 |
Drugs affecting the immune response (0,0)
|
|

Immunosuppressant therapy
(1,0)
|
08.02.01 |
Antiproliferative immunosuppressants
(2,3)
|
08.02.02 |
Corticosteroids and other immunosuppressants
(5,11)
|
08.02.03 |
Anti-lymphocyte monoclonal antibodies
(9,0)
|
08.02.04 |
Other immunomodulating drugs
(7,2)
|
|

Interferon Alfa
(3,3)
|
|

Interferon beta
(4,2)
|
|

Interferon gamma (0,0)
|
|

Aldesleukin
(1,2)
|
|

BCG bladder instillation (0,0)
|
|

Canakinumab (0,0)
|
|

Dimethyl fumarate (0,0)
|
|

Fingolimod (0,0)
|
|

Glatiramer acetate
(1,0)
|
|

Histamine (0,0)
|
|

Lenalidomide, pomalidomide, and thalidomide
(1,0)
|
|

Mifamurtide (0,0)
|
|

Natalizumab
(0,1)
|
|

Teriflunomide (0,0)
|
08.03 |
Sex hormones and hormone antagonists in malignant disease (0,0)
|
08.03.01 |
Oestrogens
(2,0)
|
08.03.02 |
Progestogens
(3,1)
|
08.03.03 |
Androgens (0,0)
|
08.03.04 |
Hormone antagonists (0,0)
|
08.03.04.01 |
Breast cancer
(5,2)
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues
(0,1)
|
|

Gonadorelin analogues
(2,1)
|
|

Anti-androgens
(6,6)
|
|

Gonadotrophin-releasing hormone antagonists (0,0)
|
08.03.04.03 |
Somatostatin analogues
(3,1)
|
|
|
|